A5082944296- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Childhood Cancer Survivors' Quality of Life
- Histone Deacetylase Inhibitors Research
- Hematopoietic Stem Cell Transplantation
- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Neutropenia and Cancer Infections
- Cancer Genomics and Diagnostics
- Immune Cell Function and Interaction
- Epigenetics and DNA Methylation
- Cancer therapeutics and mechanisms
- Adolescent and Pediatric Healthcare
- Hematological disorders and diagnostics
- Lung Cancer Research Studies
- Blood disorders and treatments
- Eosinophilic Disorders and Syndromes
- Monoclonal and Polyclonal Antibodies Research
- Retinoids in leukemia and cellular processes
- Pharmaceutical studies and practices
Cleveland Clinic
2016-2025
Cancer Institute (WIA)
2012-2025
Sidney Kimmel Cancer Center
2009-2024
Johns Hopkins University
2009-2024
The University of Kansas Cancer Center
2024
Memorial Sloan Kettering Cancer Center
2024
Mayo Clinic in Arizona
2024
Dana-Farber Cancer Institute
2018-2024
Medical College of Wisconsin
2024
Shaare Zedek Medical Center
2024
The prognosis for adults with relapsed acute lymphoblastic leukemia is poor. We sought to determine whether inotuzumab ozogamicin, an anti-CD22 antibody conjugated calicheamicin, results in better outcomes patients or refractory than does standard therapy.
PURPOSE Inotuzumab ozogamicin (CMC-544) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to calicheamicin, potent cytotoxic agent. This was phase I study determine the maximum-tolerated dose (MTD), safety, and preliminary efficacy inotuzumab in expanded MTD cohort patients with relapsed or refractory CD22(+) B-cell non-Hodgkin's lymphoma (NHL). PATIENTS AND METHODS administered intravenously as single once every 3 4 weeks at doses ranging from...
Background Inotuzumab ozogamicin (InO) is an antibody‐drug conjugate used for adults with relapsed/refractory B‐cell precursor (BCP) acute lymphoblastic leukemia (ALL). The INotuzumab Ozogamicin trial to inVestigAte Tolerability and Efficacy (INO‐VATE) previously reported improved outcomes InO versus standard‐of‐care (SoC) chemotherapy. This article reports the final INO‐VATE results (≥2 years of follow‐up) additional analyses patient characteristics associated outcomes. Methods Between...
Adults with relapsed/refractory acute lymphoblastic leukemia have an unfavourable prognosis, which is influenced by disease and patient characteristics. To further evaluate these characteristics, a retrospective analysis of 1,706 adult patients Ph-negative B-precursor diagnosed between 1990-2013 was conducted using data reflecting the standard care from 11 study groups large centers in Europe United States. Outcomes included complete remission, overall survival, realization stem cell...
The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of ALL subtypes based immunophenotype and cytogenetic/molecular markers; risk assessment stratification risk-adapted therapy; treatment strategies Philadelphia chromosome (Ph)-positive Ph-negative both adolescent young adult patients; supportive care considerations. Given complexity regimens required measures, Panel recommends that patients be treated at a specialized cancer center with expertise in...
Abstract Purpose: TTI-621 (SIRPα-IgG1 Fc) is a novel checkpoint inhibitor that activates antitumor activity by blocking the CD47 “don't eat me” signal. This first-in-human phase I study (NCT02663518) evaluated safety and of in relapsed/refractory (R/R) hematologic malignancies. Patients Methods: with R/R lymphoma received escalating weekly intravenous to determine maximum tolerated dose (MTD). During expansion, patients various malignancies single-agent at MTD; was combined rituximab B-cell...
Many older adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have a relapse despite having measurable residual disease (MRD)-negative complete remission combination chemotherapy. The addition of blinatumomab, bispecific T-cell engager molecule that is approved for the treatment relapsed, refractory, and MRD-positive BCP-ALL, may efficacy in patients MRD-negative remission.
The rapidly increasing use of pegasparaginase (pegASNase) in adults, after a half century asparaginase (ASNase) children, has prompted need for guidelines the management and prevention toxicities asparagine depletion adults. Accordingly, an initial set recommendations are provided herein. Major advantages pegASNase its 2–3-week duration action, contrast to less than 3 days with native ASNase, flexibility intravenous or intramuscular administration associated patient physician convenience....
Abstract BACKGROUND African‐American patients have been under‐represented in oncology clinical trials. Better understanding barriers to participation may help increase the accrual of onto METHODS Two hundred eighteen with malignant disease (72 and 146 white patients) were recruited from Duke Cancer Clinic Oncology Outreach Clinics (DOORS). Patients interviewed using a standardized survey. Questions included patients' knowledge cancer, religious/spiritual beliefs, satisfaction medical care,...
Purpose Inotuzumab ozogamicin (INO) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to calicheamicin, potent cytotoxic agent. We performed phase I/II study determine the maximum-tolerated dose (MTD), safety, efficacy, and pharmacokinetics INO plus rituximab (R-INO) for treatment relapsed/refractory CD20 + /CD22 B-cell non-Hodgkin lymphoma (NHL). Patients Methods A dose-escalation MTD R-INO was followed by expanded cohort further evaluate...
Purpose To investigate the risk and outcomes of second hematologic malignancies (SHMs) in a population-based cohort patients with well-differentiated thyroid cancer (WDTC) treated or not radioactive iodine (RAI). Methods Patients WDTC were identified from SEER registries. Competing regression analysis was performed to calculate risks SHMs that occurred after treatment SHM development assessed. Results Of 148,215 WDTC, 53% received surgery alone 47% RAI. In total, 783 developed an median...